Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase 1 Completed
23 enrolled
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Phase 1 Completed
167 enrolled
OncoCAIX
Phase 1 Completed
20 enrolled
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Phase 1 Completed
145 enrolled
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Phase 1 Completed
31 enrolled
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 1 Completed
26 enrolled
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Phase 1 Completed
32 enrolled
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
ABEMA Alone or in COMBO With MK-6482
Phase 1 Completed
11 enrolled 9 charts
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Phase 1 Completed
41 enrolled
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
Phase 1 Completed
11 enrolled
TIL Therapy for Metastatic Renal Cell Carcinoma
Phase 1 Completed
5 enrolled 8 charts
IVY
Phase 1 Completed
353 enrolled
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
Phase 1 Completed
60 enrolled
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Phase 1 Completed
43 enrolled
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
96 enrolled
DUET-3
Phase 1 Completed
198 enrolled
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Phase 1 Completed
12 enrolled
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Phase 1 Completed
42 enrolled 17 charts
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
Phase 1 Completed
30 enrolled
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Phase 1 Completed
22 enrolled
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Phase 1 Completed
52 enrolled 21 charts
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Phase 1 Completed
29 enrolled
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
Phase 1 Completed
23 enrolled
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
PIVOT IO 011
Phase 1 Completed
30 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
ZIRDOSE-CP
Phase 1 Completed
10 enrolled
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled 13 charts
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Phase 1 Completed
24 enrolled
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
Phase 1 Completed
65 enrolled
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Phase 1 Completed
40 enrolled
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1 Completed
38 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
Phase 1 Completed
12 enrolled
A Bioequivalence Study of Sunitinib Malate Capsules.
Phase 1 Completed
24 enrolled
DUET-4
Phase 1 Completed
78 enrolled
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Phase 1 Completed
69 enrolled
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Phase 1 Completed
193 enrolled
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 Completed
69 enrolled
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Phase 1 Completed
298 enrolled
DUET-2
Phase 1 Completed
150 enrolled
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Phase 1 Completed
104 enrolled 23 charts
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Phase 1 Completed
18 enrolled 15 charts
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Phase 1 Completed
26 enrolled 11 charts
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase 1 Completed
210 enrolled
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts